Recently, CXCL9 was investigated as a critical chemokine that can recruit and activate immune cells, particularly T lymphocytes, to the tumor microenvironment, thereby enhancing anti-tumor immunity in TNBC [40, 41]. Here, CXCL9 is linked to neoplasm.